Comparing 2 vs 3 HPV Vaccine Doses in Women Ages 27-45
This study is comparing two different ways to give the 9-valent HPV vaccine (which protects against Human Papillomavirus, a common infection that can cause certain cancers) to women aged 27 to 45. Researchers want to see if two doses of the vaccine work as well as the standard three doses in creating an immune response (your body's defense against infection). You would be randomly assigned to receive either two or three doses of the vaccine. The study will measure your immune response by checking for specific antibodies (proteins made by your immune system) at 1, 7, and 12 months after your first dose. The study is currently enrolling about 618 participants, but its overall status is unclear.
- Study design
- This is an interventional study where participants are randomly assigned to one of two groups (2-dose or 3-dose vaccine). Approximately 618 women will participate.
- What's involved
- You would receive either two or three vaccine doses over 6 months and provide four blood samples over a 12-month period. If in the 2-dose group, you'll be offered a third dose after the final blood draw.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your immune response will be measured at 1, 7, and 12 months after your first vaccination.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Abbey B Berenson, MD, PhD · PRINCIPAL_INVESTIGATOR · University of Texas
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Short-term human papillomavirus (HPV) type-specific antibody response for type HPV-6Month 1
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-6, measured as number of participants.
- Short-term human papillomavirus (HPV) type-specific antibody response for type HPV-6Month 7
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-6, measured as number of participants.
- Short-term human papillomavirus (HPV) type-specific antibody response for type HPV-6Month 12
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-6, measured as number of participants.
- Short-term HPV type-specific antibody response for type HPV-11Month 1
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-11, measured as number of participants.
- Short-term HPV type-specific antibody response for type HPV-11Month 7
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-11, measured as number of participants.
- Short-term HPV type-specific antibody response for type HPV-11Month 12
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-11, measured as number of participants.
- Short-term HPV type-specific antibody response for type HPV-16Month 1
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-16, measured as number of participants.
- Short-term HPV type-specific antibody response for type HPV-16Month 7
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-16, measured as number of participants.
- Short-term HPV type-specific antibody response for type HPV-16Month 12
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-16, measured as number of participants.
- Short-term HPV type-specific antibody response for type HPV-18Month 1
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-18, measured as number of participants.
- Short-term HPV type-specific antibody response for type HPV-18Month 7
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-18, measured as number of participants.
- Short-term HPV type-specific antibody response for type HPV-18Month 12
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-18, measured as number of participants.
- Short-term HPV type-specific antibody response for type HPV-31Month 1
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-31, measured as number of participants.
- Short-term HPV type-specific antibody response for type HPV-31Month 7
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-31, measured as number of participants.
- Short-term HPV type-specific antibody response for type HPV-31Month 12
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-31, measured as number of participants.
- Short-term HPV type-specific antibody response for type HPV-33Month 1
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-33, measured as number of participants.
- Short-term HPV type-specific antibody response for type HPV-33Month 7
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-33, measured as number of participants.
- Short-term HPV type-specific antibody response for type HPV-33Month 12
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-33, measured as number of participants.
- Short-term HPV type-specific antibody response for type HPV-45Month 1
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-45, measured as number of participants.
- Short-term HPV type-specific antibody response for type HPV-45Month 7
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-45, measured as number of participants.
- Short-term HPV type-specific antibody response for type HPV-45Month 12
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-45, measured as number of participants.
- Short-term HPV type-specific antibody response for type HPV-52Month 1
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-52, measured as number of participants.
- Short-term HPV type-specific antibody response for type HPV-52Month 7
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-52, measured as number of participants.
- Short-term HPV type-specific antibody response for type HPV-52Month 12
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-52, measured as number of participants.
- Short-term HPV type-specific antibody response for type HPV-58Month 1
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-58, measured as number of participants.
- Short-term HPV type-specific antibody response for type HPV-58Month 7
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-58, measured as number of participants.
- Short-term HPV type-specific antibody response for type HPV-58Month 12
Yes/No for seroconversion, defined as changing from seronegative (antibody titer below established threshold) to seropositive (antibody titer above established threshold) for HPV-58, measured as number of participants.